Based on recent cash burn, AGY's funds will run out by the end of Q2 2024 (late June). No MD waits until there's a risk of appointing administrators; if they're going to do a cap raise (IMO it's highly likely), it'll probably occur in late-Q1.
Based on peer comparisons, there's a good chance that the resource update won't move the needle much at all, and there's every chance that the filtration issues could take several more months to sort out. Assuming that occurs, it's certainly possible that AGY could slide towards the 10-12 cent range by mid Q1, particularly with the seasonal weakness of Chinese New Year (early Feb 2024).
Even if AGY can get the filtration issues sorted very soon, it's going to take a while to ramp up, and we still won't have any income because we don't have an offtake. So even if they could magically get it to nameplate by late Q1, there's still no income to avoid a cap raise. To avoid a cap raise (or debt), AGY needs the 10 ktpa approval ASAP so that the funding/offtake partner will sign on the dotted line. Until that occurs, there is no income regardless of how much they can produce.
- Forums
- ASX - By Stock
- AGY
- General Discussion AGY
General Discussion AGY, page-19931
-
- There are more pages in this discussion • 3,329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGY (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
-0.008(8.60%) |
Mkt cap ! $123.7M |
Open | High | Low | Value | Volume |
9.0¢ | 9.3¢ | 8.5¢ | $362.9K | 4.093M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 459867 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 93664 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 459867 | 0.085 |
3 | 99873 | 0.084 |
4 | 169062 | 0.083 |
3 | 336585 | 0.082 |
2 | 114691 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 93664 | 1 |
0.088 | 232558 | 1 |
0.089 | 69615 | 2 |
0.090 | 91167 | 2 |
0.091 | 52101 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AGY (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online